Navigation Links
Nuvilex Launches Video Marketing Campaign
Date:6/1/2009

CHERRY HILL, N.J., June 1 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), an emerging healthcare consumer products company is now airing the first in a series of videos to promote the company and its products. Chairman and CEO Martin Schmieg leads off with an overview of the company's innovative and diverse product lines. This video is now running on the Nuvilex website at www.nuvilex.com and will be featured in corporate presentations and the Company's business development efforts.

Next up is a video commercial to promote Nuvilex' Last Shot Hangover Remedy. This new product eases hangover symptoms and is expected to launch Q3 2009 (July) in North America and Q4 2009 (October) worldwide. The Last Shot Hangover Remedy will air on various platforms including television, movie previews, and the Internet. Miller + Partners has been engaged to produce Nuvilex' video campaign.

About Miller + Partners

For over two decades, the consulting team at MILLER+PARTNERS has helped hundreds of top companies leverage the screen to communicate better, build brand awareness and heighten the users experience. Our Powermercial(TM) products enable our clients to reach across the social and sharing networks with engaging, entertaining and market focused video. For more information about Miller + Partners please visit us at www.GreatVideoSells.com.

About Nuvilex, Inc.

Nuvilex, formerly eFoodSafety.com, is an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products. The company's focus is on developing, licensing and commercializing healthcare products that address the health needs of consumers worldwide. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., a diversified skin products technology company serving the fast-growing body art, aesthetic, cosmetic and skin therapy markets. More information is available at: http://www.nuvilex.com or www.freedom2inc.com.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Investor Relations Contacts:

    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088
    Email: bbarnes@nuvilex.com

    Stephanie Carrington/Amy Glynn
    The Ruth Group
    Ph: 646-536-7017/7023
    Email: scarrington@theruthgroup.com
    Email: aglynn@theruthgroup.com


    Press Contacts:

    Pat Arcand
    Arcand & Madison Public Relations
    Ph: 617-576-7777
    Email: pat@am-pr.com


'/>"/>
SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan
2. Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the Worlds First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand
3. Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex
4. Nuvilex, Inc. Announces Monthly Investor Conference Call
5. Nuvilex Advances Release of Citroxin(TM) Antiviral Surface Cleaner to Help Combat Swine Flu
6. Nuvilex, Inc. Announces Investor Conference Call and Open House
7. Nuvilex, Inc.s Marketing Partner, CK41 to Launch purEffect(TM) in May
8. Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign
9. Nuvilex Provides Conference Call Replay Information
10. Nuvilex, Inc. Launches Spring Break Initiatives Designed to Raise Visibility Among Key Demographic Group
11. Nuvilex Infinitink Tattoo Ink Featured on PBS alt.news 26:46 TV Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
Breaking Medicine Technology: